Metropolis Healthcare Collaborates with Qritive for Cutting-Edge Cancer Detection
India, Mumbai, 14th February 2024: Metropolis Healthcare Limited, India’s leading diagnostic service provider, today announces its collaboration with QritiveTM, a leading provider of AI solutions for pathology labs globally. This partnership is set to augment Metropolis' cancer diagnosis capabilities through the integration of state-of-the-art AI technology.
The integration includes the adoption of the PantheonTM image management system (IMS) and the utilization of Qritive's AI products, marking a significant leap forward in incorporating Artificial Intelligence into pathology workflows for enhanced efficiency and precision in diagnostics. Commenting on the partnership, Mr. Surendran Chemmenkottil, CEO, Metropolis Healthcare Limited said: "In today's healthcare landscape, AI plays a pivotal role in supporting pathologists and clinicians, enhancing the cancer diagnosis process. Qritive's AI platform is expected to streamline routine cancer diagnosis, ensuring quality control, reducing diagnosis time, and enhancing overall productivity. The integration of AI insights into pathology workflows will significantly impact various tissue diagnoses, providing quicker turnaround times and delivering high-quality results. This collaboration reinforces our commitment to setting a new standard in cancer care, particularly in supporting clinicians in making effective treatment decisions for prostate cancer detection." Dr. Kirti Chadha, Chief Scientific Officer & Senior Oncopathologist at Metropolis Healthcare, stated: “Our commitment is unwavering in providing precise, timely, and personalized cancer diagnoses for every patient. As cancer prevalence rises and personalized medicine advances, diagnostic complexity increases, adding to
. Read more on livemint.com
